Related Experiment Video

Updated: Sep 23, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

Genes and their polymorphisms in mono- and multifactorial cardiomyopathies: towards pharmacogenomics in heart failure

Philippe Charron1, Michel Komajda

  • 1Department of Cardiology and Genetics Laboratory, Association Claude Bernard, Université Paris VI, Hôpital Pitié-Salpêtrière, Paris, France. pcharron@infobiogen.fr

Pharmacogenomics
|June 8, 2002
PubMed

Insights

Cardiomyopathies, including dilated (DCM) and hypertrophic (HCM) types, cause cardiac dysfunction and have significant socioeconomic impacts. Genetic factors are increasingly understood, paving the way for pharmacogenetics in heart failure treatment.

Area of Science:

  • Cardiology
  • Genetics
  • Pharmacology

Background:

  • Cardiomyopathies encompass dilated (DCM), hypertrophic (HCM), and restrictive types, all leading to cardiac dysfunction.
  • These conditions result in major complications like heart failure and sudden death, with significant socioeconomic implications.
  • DCM is a leading cause for heart transplantation, while HCM is a primary cause of sudden death in young athletes.

Purpose of the Study:

  • To explore the role of genetic background in the development and progression of cardiomyopathies.
  • To investigate the potential interactions between pharmacological treatments and genetic polymorphisms.
  • To lay the groundwork for applying pharmacogenetics in managing heart failure.

Main Methods:

  • Review of recent studies on genetic factors in cardiomyopathies.
  • Analysis of preliminary data on gene-drug interactions.
  • Exploration of underlying disease mechanisms.

Main Results:

  • Understanding of genetic underpinnings in monogenic and multifactorial cardiomyopathies has advanced.
  • Preliminary evidence suggests interactions between genetic polymorphisms and pharmacological treatments.
  • These findings represent initial steps toward pharmacogenetic applications in heart failure.

Conclusions:

  • Genetic background plays a crucial role in cardiomyopathy development and progression.
  • Pharmacogenetic approaches hold promise for personalized heart failure therapy.
  • Further research is needed to fully elucidate gene-drug interactions for clinical application.

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...